Terms: = Germ cell tumor AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
824 results:
1. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
[TBL] [Abstract] [Full Text] [Related]
2. Evaluating the human neurotoxicity and toxicological interactions impact of co-occurring regulated and emerging mycotoxins.
de Sá SVM; Sousa Monteiro C; Fernandes JO; Pinto E; Faria MA; Cunha SC
Food Res Int; 2024 May; 184():114239. PubMed ID: 38609220
[TBL] [Abstract] [Full Text] [Related]
3. BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
4. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression.
Nakamura M; Yoshimitsu M; Magara T; Kano S; Kato H; Morita A
Exp Dermatol; 2024 Mar; 33(3):e15062. PubMed ID: 38532566
[TBL] [Abstract] [Full Text] [Related]
5. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
6. Loss of miR-101-3p in melanoma stabilizes genomic integrity, leading to cell death prevention.
Lämmerhirt L; Kappelmann-Fenzl M; Fischer S; Meier P; Staebler S; Kuphal S; Bosserhoff AK
Cell Mol Biol Lett; 2024 Mar; 29(1):29. PubMed ID: 38431560
[TBL] [Abstract] [Full Text] [Related]
7. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Mol Cancer; 2024 Feb; 23(1):40. PubMed ID: 38383439
[TBL] [Abstract] [Full Text] [Related]
8. Duodenal malignant melanoma: Primary and metastatic case series and literature review.
Zhou B; Li X; Liu J; Peng L; Liu X
Medicine (Baltimore); 2024 Feb; 103(6):e37138. PubMed ID: 38335433
[TBL] [Abstract] [Full Text] [Related]
9. Targeting cd20-expressing malignant melanoma cells augments BRAF inhibitor killing.
Mukhtar AB; Morgan HJ; Gibbs A; Davies GE; Lovatt C; Patel GK
Br J Dermatol; 2024 Apr; 190(5):729-739. PubMed ID: 38288865
[TBL] [Abstract] [Full Text] [Related]
10. Characterizing Immune Infiltration in Esthesioneuroblastoma Subtypes Through Gene Expression Deconvolution.
Batchu S; Gill AS; Karsy M
World Neurosurg; 2024 Mar; 183():e928-e935. PubMed ID: 38246527
[TBL] [Abstract] [Full Text] [Related]
11. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
12. Apocynin exerts neuroprotective effects in fumonisin b1-induced neurotoxicity via attenuation of oxidative stress and apoptosis in an animal model.
Krishnaswamy K; Manasa V; Khan MT; Serva Peddha M
J Food Sci; 2024 Feb; 89(2):1280-1293. PubMed ID: 38193205
[TBL] [Abstract] [Full Text] [Related]
13. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register.
Molina-Collada J; Alonso F; Otero L; Bohórquez C; Díaz Torné C; Pérez García C; Blanco Madrigal JM; Vela P; Álvaro-Gracia JM; Castrejón I;
Semin Arthritis Rheum; 2024 Feb; 64():152341. PubMed ID: 38128174
[TBL] [Abstract] [Full Text] [Related]
14. Bioinspired Lipoproteins of Furoxans-Gemcitabine Preferentially Targets Glioblastoma and Overcomes Radiotherapy Resistance.
Sun M; Xie H; Zhang W; Li X; Jiang Z; Liang Y; Zhao G; Huang N; Mao J; Liu G; Zhang Z
Adv Sci (Weinh); 2024 Feb; 11(6):e2306190. PubMed ID: 38049204
[TBL] [Abstract] [Full Text] [Related]
15. Cytokine Profile in Development of Glioblastoma in Relation to Healthy Individuals.
Jarmuzek P; Defort P; Kot M; Wawrzyniak-Gramacka E; Morawin B; Zembron-Lacny A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003396
[TBL] [Abstract] [Full Text] [Related]
16. Teratoma pathology and genomics in anti-NMDA receptor encephalitis.
Jang Y; Lee K; Lee C; Chu K; Lee SK; Won JK; Lee ST
Ann Clin Transl Neurol; 2024 Jan; 11(1):225-234. PubMed ID: 37986706
[TBL] [Abstract] [Full Text] [Related]
17. Combining CSPG4-CAR and cd20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract] [Full Text] [Related]
18. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System tumors.
Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
[TBL] [Abstract] [Full Text] [Related]
19. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.
Martinez-Morilla S; Moutafi M; Fernandez AI; Jessel S; Divakar P; Wong PF; Garcia-Milian R; Schalper KA; Kluger HM; Rimm DL
Oncoimmunology; 2023; 12(1):2260618. PubMed ID: 37781235
[TBL] [Abstract] [Full Text] [Related]
20. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
[TBL] [Abstract] [Full Text] [Related]
[Next]
